UTHR - United Therapeutics Corp Stock Price, Fair Value and News

234.88USD-1.07 (-0.45%)Delayed as of 26 Apr 2024, 12:28 pm ET

Market Summary

USD234.88-1.07

Delayedas of 26 Apr 2024, 12:28 pm

-0.45%

UTHR Alerts

2 major insider sales recently.

UTHR Stock Price

View Fullscreen

UTHR RSI Chart

UTHR Valuation

Market Cap

11.1B

Price/Earnings (Trailing)

11.28

Price/Sales (Trailing)

4.77

EV/EBITDA

7.14

Price/Free Cashflow

14.85

UTHR Price/Sales (Trailing)

UTHR Profitability

EBT Margin

54.75%

Return on Equity

16.46%

Return on Assets

13.74%

Free Cashflow Yield

6.73%

UTHR Fundamentals

UTHR Revenue

Revenue (TTM)

2.3B

Rev. Growth (Yr)

25.07%

Rev. Growth (Qtr)

0.87%

UTHR Earnings

Earnings (TTM)

984.8M

Earnings Growth (Yr)

64.35%

Earnings Growth (Qtr)

-18.87%

Breaking Down UTHR Revenue

52 Week Range

204.44261.54

(Low)(High)

Last 7 days

-0.4%

Last 30 days

-4.8%

Last 90 days

8.2%

Trailing 12 Months

4.5%

How does UTHR drawdown profile look like?

UTHR Financial Health

Current Ratio

4.41

UTHR Investor Care

Shares Dilution (1Y)

1.63%

Diluted EPS (TTM)

19.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.0B	2.1B	2.2B	2.3B
2022	1.8B	1.8B	1.9B	1.9B
2021	1.5B	1.6B	1.7B	1.7B
2020	1.4B	1.4B	1.4B	1.5B
2019	1.6B	1.5B	1.5B	1.4B
2018	1.7B	1.7B	1.7B	1.6B
2017	1.6B	1.6B	1.7B	1.7B
2016	1.5B	1.6B	1.6B	1.6B
2015	1.3B	1.3B	1.4B	1.5B
2014	1.2B	1.2B	1.2B	1.3B
2013	957.0M	1.0B	1.1B	1.1B
2012	784.9M	826.7M	867.4M	916.1M
2011	629.5M	678.5M	711.7M	743.2M
2010	405.1M	455.8M	527.2M	592.9M
2009	0	307.3M	333.1M	358.9M
2008	0	0	0	281.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of United Therapeutics Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 24, 2024	rothblatt martine a	acquired	466,164	129	3,600	chairperson & ceo
Apr 24, 2024	rothblatt martine a	sold	-859,730	238	-3,600	chairperson & ceo
Apr 23, 2024	rothblatt martine a	sold	-850,983	236	-3,600	chairperson & ceo
Apr 23, 2024	rothblatt martine a	acquired	466,164	129	3,600	chairperson & ceo
Apr 22, 2024	rothblatt martine a	acquired	466,164	129	3,600	chairperson & ceo
Apr 22, 2024	dwek raymond	back to issuer	-702,180	234	-3,000	-
Apr 22, 2024	rothblatt martine a	sold	-851,298	236	-3,600	chairperson & ceo
Apr 22, 2024	dwek raymond	acquired	264,090	88.03	3,000	-
Apr 19, 2024	rothblatt martine a	sold	-852,876	236	-3,600	chairperson & ceo
Apr 19, 2024	rothblatt martine a	acquired	466,164	129	3,600	chairperson & ceo

Which funds bought or sold UTHR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	DekaBank Deutsche Girozentrale	reduced	-1.56	1,775,000	22,392,000	0.04%
Apr 24, 2024	Assenagon Asset Management S.A.	added	3.72	1,434,100	18,586,000	0.04%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	reduced	-0.65	14,000	386,000	-%
Apr 24, 2024	Greylin Investment Management, Inc	reduced	-1.72	8,510	327,351	0.05%
Apr 24, 2024	Robeco Institutional Asset Management B.V.	added	111	22,658,100	41,364,800	0.09%
Apr 24, 2024	Polaris Capital Management, LLC	reduced	-8.84	-1,493,210	29,852,100	1.49%
Apr 24, 2024	AlphaCentric Advisors LLC	new	-	3,675,520	3,675,520	2.22%
Apr 24, 2024	CENTRAL TRUST Co	unchanged	-	315	7,352	-%
Apr 23, 2024	FIFTH THIRD BANCORP	reduced	-68.53	-242,514	118,765	-%
Apr 23, 2024	WEDGE CAPITAL MANAGEMENT L L P/NC	new	-	39,178,500	39,178,500	0.63%

Are Funds Buying or Selling UTHR?

Are funds buying UTHR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own UTHR

No. of Funds

UTHR Alerts

2 major insider sales recently.

Unveiling United Therapeutics Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	rothblatt martine a	7.8%	3,900,308	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	6.1%	2,858,888	SC 13G/A
Feb 13, 2024	renaissance technologies llc	4.62%	2,170,214	SC 13G/A
Feb 13, 2024	vanguard group inc	9.95%	4,673,678	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	wellington management group llp	8.07%	3,794,010	SC 13G/A
Jan 24, 2024	blackrock inc.	11.3%	5,294,844	SC 13G/A
Jul 10, 2023	wellington management group llp	10.01%	4,688,824	SC 13G/A
Mar 08, 2023	blackrock inc.	10.2%	4,726,986	SC 13G/A
Feb 14, 2023	avoro capital advisors llc	6.3%	2,865,000	SC 13G/A

Recent SEC filings of United Therapeutics Corp

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 19, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 15, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading

Peers (Alternatives to United Therapeutics Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

United Therapeutics Corp News

Latest updates

United Therapeutics Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	0.9%	615	609	597	507	492	516	467	462	415	445	447	379	385	380	362	356	311	402	374	363	381
Costs and Expenses	25.6%	355	282	283	223	316	202	265	174	245	216	224	444	320	159	222	190	248	218	152	1,019	250
S&GA Expenses	3.6%	132	128	130	87.00	163	98.00	142	79.00	128	109	113	-	-	-	-	-	-	-	-	-	-
R&D Expenses	78.7%	151	85.00	89.00	83.00	94.00	66.00	94.00	69.00	83.00	79.00	74.00	304	126	69.00	90.00	73.00	114	86.00	86.00	897	139
EBITDA Margin	3.7%	0.60*	0.57*	0.58*	0.52*	0.53*	0.53*	0.49*	0.53*	0.39*	0.38*	0.41*	0.38*	-	-	-	-	-	-	-	-	-
Interest Expenses	-3.2%	15.00	16.00	15.00	14.00	12.00	9.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	6.00	8.00	10.00	12.00	12.00	10.00	4.00
Income Taxes	-7.0%	78.00	84.00	76.00	51.00	47.00	73.00	35.00	69.00	28.00	42.00	44.00	4.00	16.00	48.00	27.00	34.00	16.00	35.00	45.00	-156	27.00
Earnings Before Taxes	-16.0%	295	352	335	292	179	313	151	309	141	204	217	33.00	114	219	134	172	68.00	167	250	-650	92.00
EBT Margin	4.2%	0.55*	0.53*	0.53*	0.47*	0.49*	0.49*	0.45*	0.49*	0.35*	0.34*	0.37*	0.33*	-	-	-	-	-	-	-	-	-
Net Income	-18.9%	217	268	259	241	132	239	116	240	112	163	173	28.00	99.00	171	107	138	53.00	132	205	-494	65.00
Net Income Margin	3.7%	0.42*	0.41*	0.41*	0.37*	0.38*	0.38*	0.35*	0.39*	0.28*	0.28*	0.30*	0.27*	-	-	-	-	-	-	-	-	-
Free Cashflow	-74.3%	72.00	281	62.00	334	89.00	190	110	275	104	162	132	79.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	2.0%	7,167	7,024	6,681	6,346	6,045	5,782	5,543	5,360	5,169	5,049	4,845	4,641	4,615	4,411	4,219	4,026	3,913	4,000	3,899	3,727	3,401
Current Assets	2.7%	3,551	3,459	3,213	3,193	3,380	3,056	2,684	2,587	2,324	2,386	2,318	2,014	2,167	1,868	1,894	1,846	1,865	1,933	2,140	1,943	1,768
Cash Equivalents	9.0%	1,208	1,108	1,067	1,164	961	967	795	813	895	909	942	832	739	670	685	875	738	720	881	791	669
Inventory	7.2%	112	104	103	103	102	91.00	90.00	88.00	94.00	97.00	90.00	92.00	87.00	88.00	90.00	92.00	93.00	94.00	97.00	96.00	101
Net PPE	5.4%	1,045	992	939	897	862	841	791	784	781	727	716	714	732	736	744	739	739	678	709	701	700
Liabilities	-9.9%	1,182	1,312	1,270	1,223	1,248	1,219	1,225	1,184	1,210	1,219	1,205	1,196	1,220	1,128	1,126	1,077	1,133	1,284	1,332	1,389	593
Current Liabilities	8.1%	804	744	370	325	343	316	332	293	305	320	311	302	323	259	255	207	463	470	464	270	277
Shareholder's Equity	4.8%	5,985	5,712	5,411	5,123	4,797	4,562	4,318	4,176	3,959	3,830	3,640	3,445	3,395	3,283	3,094	2,949	2,780	2,716	2,558	2,319	2,789
Retained Earnings	3.7%	6,027	5,810	5,542	5,283	5,042	4,910	4,671	4,555	4,315	4,203	4,040	3,868	3,839	3,740	3,569	3,462	3,325	3,273	3,140	2,935	3,435
Additional Paid-In Capital	1.0%	2,549	2,524	2,498	2,457	2,388	2,315	2,292	2,254	2,245	2,226	2,197	2,173	2,149	2,126	2,105	2,068	2,048	2,026	2,002	1,968	1,940
Shares Outstanding	0.1%	47.00	47.00	47.00	47.00	46.00	46.00	45.00	45.00	45.00	45.00	45.00	45.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	9,138	-	-	-	10,532	-	-	-	7,912	-	-	-	4,726	-	-	-	2,977	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-56.5%	151	346	106	375	128	259	127	289	175	186	148	90.00	126	251	164	215	103	185	133	-627	85.00
Share Based Compensation	-21.3%	17.00	21.00	14.00	-12.40	65.00	-2.40	66.00	-21.10	45.00	25.00	29.00	40.00	94.00	-12.50	52.00	31.00	30.00	24.00	-37.20	29.00	3.00
Cashflow From Investing	113.4%	42.00	-313	-227	-221	-189	-94.00	-169	-359	-195	-235	-48.90	-6.30	-63.80	-271	-375	-27.60	66.00	-298	-42.60	-60.30	-72.20
Cashflow From Financing	-1321.1%	-92.80	8.00	25.00	49.00	56.00	7.00	24.00	-11.00	8.00	17.00	11.00	10.00	6.00	6.00	22.00	-50.20	-150	-48.30	0.00	809	0.00

UTHR Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Total revenues	$ 2,327.5	$ 1,936.3	$ 1,685.5
Operating expenses:
Cost of sales	257.5	151.6	122.5
Research and development	408.0	322.9	540.1
Selling, general, and administrative	477.1	482.1	467.0
Total operating expenses	1,142.6	956.6	1,129.6
Operating income	1,184.9	979.7	555.9
Interest income	162.7	45.2	16.7
Interest expense	(59.3)	(32.4)	(18.6)
Other (expense) income, net	(14.0)	(40.2)	42.2
Impairments of investments in privately-held companies	0.0	(1.7)	(2.3)
Total other income (expense), net	89.4	(29.1)	38.0
Income before income taxes	1,274.3	950.6	593.9
Income tax expense	(289.5)	(223.3)	(118.1)
Net income	$ 984.8	$ 727.3	$ 475.8
Net income per common share:
Basic (in dollars per share)	$ 21.04	$ 15.98	$ 10.60
Diluted (in dollars per share)	$ 19.81	$ 15.00	$ 10.06
Weighted average number of common shares outstanding:
Basic (in shares)	46.8	45.5	44.9
Diluted (in shares)	49.7	48.5	47.3

UTHR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,207.7	$ 961.2
Marketable investments	1,786.4	1,877.5
Accounts receivable, no allowance for 2023 and 2022	278.9	220.4
Inventories, net	111.8	102.0
Other current assets	166.2	219.2
Total current assets	3,551.0	3,380.3
Marketable investments	1,909.8	1,316.2
Goodwill and other intangible assets, net	114.2	44.5
Property, plant, and equipment, net	1,045.4	861.5
Deferred tax assets, net	394.8	327.7
Other non-current assets	151.8	114.3
Total assets	7,167.0	6,044.5
Current liabilities:
Accounts payable and accrued expenses	298.0	229.9
Line of credit (current)	400.0	0.0
Share tracking awards plan	35.4	80.8
Other current liabilities	71.0	32.5
Total current liabilities	804.4	343.2
Line of credit (non-current)	300.0	800.0
Other non-current liabilities	77.8	104.6
Total liabilities	1,182.2	1,247.8
Commitments and contingencies—Note 12
Stockholders’ equity:
Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued	0.0	0.0
Common stock, par value $.01, 245,000,000 shares authorized, 73,659,761 and 72,651,280 shares issued, and 47,040,545 and 46,032,064 shares outstanding as of December 31, 2023 and 2022, respectively	0.7	0.7
Additional paid-in capital	2,549.0	2,388.4
Accumulated other comprehensive loss	(12.8)	(55.5)
Treasury stock, 26,619,216 shares as of December 31, 2023 and 2022	(2,579.2)	(2,579.2)
Retained earnings	6,027.1	5,042.3
Total stockholders’ equity	5,984.8	4,796.7
Total liabilities and stockholders’ equity	$ 7,167.0	$ 6,044.5

About United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

CEO	Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
WEBSITE	unither.com
INDUSTRY	Biotechnology
EMPLOYEES	985

United Therapeutics Corp Frequently Asked Questions

What is the ticker symbol for United Therapeutics Corp? What does UTHR stand for in stocks?

UTHR is the stock ticker symbol of United Therapeutics Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of United Therapeutics Corp (UTHR)?

As of Thu Apr 25 2024, market cap of United Therapeutics Corp is 11.1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of UTHR stock?

You can check UTHR's fair value in chart for subscribers.

What is the fair value of UTHR stock?

You can check UTHR's fair value in chart for subscribers. The fair value of United Therapeutics Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of United Therapeutics Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for UTHR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is United Therapeutics Corp a good stock to buy?

The fair value guage provides a quick view whether UTHR is over valued or under valued. Whether United Therapeutics Corp is cheap or expensive depends on the assumptions which impact United Therapeutics Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UTHR.

What is United Therapeutics Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, UTHR's PE ratio (Price to Earnings) is 11.28 and Price to Sales (PS) ratio is 4.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UTHR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on United Therapeutics Corp's stock?

In the past 10 years, United Therapeutics Corp has provided 0.102 (multiply by 100 for percentage) rate of return.